Literature DB >> 20118960

Ofatumumab.

Michael J Keating, Argyris Dritselis, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20118960     DOI： 10.1038/nrd3100

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

1.  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Authors:  Jessica L Teeling; Wendy J M Mackus; Luus J J M Wiegman; Jeroen H N van den Brakel; Stephen A Beers; Ruth R French; Tom van Meerten; Saskia Ebeling; Tom Vink; Jerry W Slootstra; Paul W H I Parren; Martin J Glennie; Jan G J van de Winkel
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

Review 2.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

Review 3.  Antibody therapy for chronic lymphocytic leukemia.

Authors:  Beth A Christian; Thomas S Lin
Journal:  Semin Hematol       Date:  2008-04       Impact factor: 3.851

Review 4.  Chronic lymphocytic leukaemia.

Authors:  G Dighiero; T J Hamblin
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

5.  Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.

Authors:  Bertrand Coiffier; Stéphane Lepretre; Lars Møller Pedersen; Ole Gadeberg; Henrik Fredriksen; Marinus H J van Oers; James Wooldridge; Janusz Kloczko; Jerzy Holowiecki; Andrzej Hellmann; Jan Walewski; Mimi Flensburg; Jørgen Petersen; Tadeusz Robak
Journal:  Blood       Date:  2007-11-14       Impact factor: 22.113

6.  Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.

Authors:  Jessica L Teeling; Ruth R French; Mark S Cragg; Jeroen van den Brakel; Marielle Pluyter; Haichun Huang; Claude Chan; Paul W H I Parren; C Erik Hack; Michael Dechant; Thomas Valerius; Jan G J van de Winkel; Martin J Glennie
Journal:  Blood       Date:  2004-06-01       Impact factor: 22.113

7.  The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.

Authors:  Constantine S Tam; Susan O'Brien; Susan Lerner; I Khouri; A Ferrajoli; S Faderl; M Browning; Apostolia M Tsimberidou; Hagop Kantarjian; William G Wierda
Journal:  Leuk Lymphoma       Date:  2007-10

Review 8.  Clinical use of rituximab in haematological malignancies.

Authors:  I Avivi; S Robinson; A Goldstone
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640
  8 in total
  10 in total

1.  Trial Watch: Monoclonal antibodies in cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Jessica Zucman-Rossi; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 2.  Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

Authors:  Ciara L Freeman; Laurie Sehn
Journal:  Curr Oncol Rep       Date:  2018-11-27       Impact factor: 5.075

3.  Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.

Authors:  Sarwish Rafiq; Jonathan P Butchar; Carolyn Cheney; Xiaokui Mo; Rossana Trotta; Michael Caligiuri; David Jarjoura; Susheela Tridandapani; Natarajan Muthusamy; John C Byrd
Journal:  J Immunol       Date:  2013-02-15       Impact factor: 5.422

Review 4.  Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Authors:  Erika Vacchelli; Jonathan Pol; Norma Bloy; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jérôme Galon; Aurélien Marabelle; Holbrook Kohrt; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

5.  New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.

Authors:  J Nicholas; B Morgan-Followell; D Pitt; M K Racke; A Boster
Journal:  J Cent Nerv Syst Dis       Date:  2012-05-16

Review 6.  Trial Watch: Immunostimulatory cytokines.

Authors:  Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-05-07       Impact factor: 8.110

Review 7.  Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases.

Authors:  Zhiqiang An
Journal:  Protein Cell       Date:  2010-05-08       Impact factor: 14.870

8.  Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis.

Authors:  Chengxin Luo; Guixian Wu; Xiangtao Huang; Yanni Ma; Yali Zhang; Qiuyue Song; Mingling Xie; Yanni Sun; Yarui Huang; Zhen Huang; Yu Hou; Shuangnian Xu; Jieping Chen; Xi Li
Journal:  Sci Rep       Date:  2021-02-05       Impact factor: 4.379

Review 9.  Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis.

Authors:  Silvia Tenembaum; E Ann Yeh
Journal:  Front Pediatr       Date:  2020-06-25       Impact factor: 3.418

10.  Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C δ.

Authors:  Linda Lei; Sabina Muhammad; Muthana Al-Obaidi; Neil Sebire; Iek Leng Cheng; Despina Eleftheriou; Paul Brogan
Journal:  Pediatr Rheumatol Online J       Date:  2018-09-26       Impact factor: 3.054
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.